EYPT - Company ID 0001314102
The table below shows EyePoint Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $696.00K | $966.00K | $5.33M | $24.45M | $10.52M | $9.48M |
| Cost of revenue | - | - | - | - | $736.00K | $1.40M |
| Gross profit | - | - | - | - | - | - |
| R&D | $72.15M | $47.75M | $55.50M | $58.57M | $29.54M | $29.82M |
EyePoint Pharmaceuticals, Inc. reported annual revenue of $31.37M for fiscal year 2025. That is down 27.5% from $43.27M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.62M (FY 2016) to $31.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $15.24M |
| $14.49M |
| $11.86M |
| $13.88M |
| $12.97M |
| $12.75M |
| Operating income | -$87.23M | -$62.02M | -$62.23M | -$48.84M | -$32.75M | -$34.55M |
| Income tax | -$50.00K | $0.00 | $93.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$84.83M | -$59.73M | -$59.43M | -$45.20M | -$29.36M | -$30.83M |
| EPS (diluted) | -$0.99 | -$0.85 | -$0.85 | -$0.65 | -$0.54 | -$0.58 |